News

http://www.globenewswire.com/news-release/2021/05/03/2221837/0/en/Vantage-Hemp-Co-Announces-Partnership-with-Medcan-Australia-to-Supply-a-Range-of-Medicinal-CBD-Products.html

Vantage Hemp Co. Announces Partnership with Medcan Australia to Supply a Range of Medicinal CBD Products

May 03, 2021 18:07 ET | Source: Vantage Hemp

Greeley, Colorado, May 03, 2021 (GLOBE NEWSWIRE) — Vantage Hemp Co. is pleased to announce its new partnership with Medcan Australia (Medcan) and expansion into the Australian CBD market through the distribution of their pharmaceutical grade CBD extracts. 

Under the agreement, Vantage Hemp Co. will supply Medcan a range of high quality crude oil, full-spectrum oil, distillate, isolate and CBS Active Pharmaceutical Ingredient (API) products for medical use. 

“We’re pleased to join the Australian medical cannabis community. The opportunity will allow Vantage to enter the growing market to help meet the increased patient demand for CBD products.” said Christian Santi, Director of Sales and Marketing, Vantage Hemp Co. 

Vantage Hemp is now one of the most accredited extractors in the world. It has achieved EU compliance, North American GMP compliance, and the internationally recognized ICH Q7 GMP and WHO GMP certifications, which endorse the company’s CBD extracts as the highest standard found anywhere in the world. Vantage Hemp will utilize their state-of-the-art facilities by providing premium extracts that will allow the company to set the stage for a new level of standards and innovative products in Australia’s CBD market.

Santi continues, “This strategic partnership further validates the quality of our products and the strength of our science driven, data-backed value proposition. It’s another important step forward to position Vantage as a leader in CBD extraction and becoming a globally recognized brand by increasing our foothold in international markets. We’re looking forward to collaborating with Medcan to bring trusted, quality products to patients”

Medcan has quickly become a leader in the Australian medicinal CBD industry through its commitment to providing quality, accessible products to patients. The partnership reflects the companies’ shared values and commitment to meet the needs of patients by providing access to trusted, and the highest quality cannabis products on the market. 

“Now more than ever, it’s important to meet the growing interest from patients with quality products that will provide effective results.” said Craig Cochran,Founder and CEO, Medcan Australia. “Partnering with Vantage Hemp gives us the ability to extend the scope of our products to offer greater support and variety to patients across Australia. We’re proud to collaborate with Vantage Hemp to further strengthen our mutual goals and allow both companies to scale to meet demand and deliver the quality our patients expect.” 

For more information, visit vantagehemp.com. For media inquiries contact Russell Cafferty, Media Executive at rcafferty@marigoldpr.com or 437-775-0785.

About Vantage Hemp Co.

With large-scale, high volume extraction facilities, Colorado-based Vantage Hemp Co. has CBD extraction down to a science. By utilizing state-of-the-art technology and having a meticulous focus on every detail of extraction, this start-up turned industry leader consistently delivers pharmaceutical grade, GMP compliant CBD extracts (including full-spectrum oil, distillate and isolate) that companies can trust. Learn more at www.vantagehemp.com.

Medcan Australia – Medcan partners with Cann I Help to deliver Compassionate Access Program

26th October, 2020 – For immediate release

Medcan Australia participates in CMOS (Cannabinoid Medicine Observational Study)

Medcan Australia (Medcan) is pleased to announce its participation in CMOS.

CMOS is a cannabis medicine observational study that will be run in collaboration with GP’s and specialists around Australia. This study aims to recruit 20,000 Australian patients undergoing treatment with medicinal cannabis.

CMOS will benefit participating clinicians, and their patients, by providing insight into medicinal cannabis prescribing and treatment practices from clinics around Australia participating in CMOS. Insights will be provided in the form of de-identified aggregated data reports including information on product dosing/categories being prescribed, patient reported outcomes (PROs) and adverse events reported by study participants, to be released to participating clinics on a quarterly basis. This data will provide a useful resource for clinicians who may be prescribing medicinal cannabis products and wish to gain better insight into the current Australian prescribing landscape.

Prescribing doctors will have access to MEDCAN products and will collect safety and efficacy data for a range of indications including fibromyalgia, chronic pain syndromes, PTSD, epilepsy and other mental health and neurological conditions.

Further information and participation criteria can be requested at: www.medcanaustralia.com.au/contact/

Comments from Craig Cochran – Managing Director, Founder, Medcan Australia:

Medcan Australia Founder and CEO, Craig Cochran said: “Medcan Australia are very excited to be a part of the CMOS study. Studies like CMOS are extremely important to build credible data around medicinal cannabis products and patient responses for various indications. As a leader in the Australian medicinal cannabis industry, Medcan Australia is proud to support the advancement of medicinal cannabis research both locally and internationally”

Background

Medcan Australia was founded in 2016 and was one of the first Australian companies to be licensed by the Office of Drug Control (ODC) to cultivate and produce Medicinal Cannabis, manufacture Medicinal Cannabis products and import and export Medicinal Cannabis products.  The company was founded with a single vision to provide Australian patients with high quality, fair priced Medicinal Cannabis products.

Medcan have a dedicated Cultivation, Production, Manufacture and Pharmaceutical wholesaling facility located in Brisbane Australia.  Medcan currently import a range of TGO93 compliant MEDCAN branded products for supply to Australian patients. 

For Further Information please contact:

Gareth Ball 

+61414860512

1800 633 226
Po Box 4579, Springfield, QLD, Australia, 4300

gareth@medcanaustralia.com.au

www.medcanaustralia.com.au

17th June 2020The Australian Government has delivered improved access to global markets for agricultural narcotic exports for medicinal cannabis and hemp industries.

https://minister.awe.gov.au/littleproud/media-releases/narcotic-exports-market-access

29th January, 2020 – For immediate release

11th of November

10th of October

8th of October 

RAVENQUEST RECEIVES HEALTH CANADA PERMIT FOR EXPORT TO AUSTRALIA       

                                                                                                   

2nd of July 2019

2nd July 2019 Medcan Secured its Research Licence

19th of February 2019

Medcan Looking for new Investors – Press Release FEB 2019.1 (003)